Search

Your search keyword '"Kostyanev T"' showing total 2 results
Start Over Author "Kostyanev T" Journal nature communications
2 results on '"Kostyanev T"'

1. International and regional spread of carbapenem-resistant Klebsiella pneumoniae in Europe.

Author

Budia-Silva M, Kostyanev T, Ayala-Montaño S, Bravo-Ferrer Acosta J, Garcia-Castillo M, Cantón R, Goossens H, Rodriguez-Baño J, Grundmann H, and Reuter S

Subjects
Europe epidemiology, Humans, Carbapenem-Resistant Enterobacteriaceae genetics, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Carbapenem-Resistant Enterobacteriaceae drug effects, Microbial Sensitivity Tests, Multilocus Sequence Typing, Klebsiella pneumoniae genetics, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae isolation & purification, Klebsiella Infections epidemiology, Klebsiella Infections microbiology, Carbapenems pharmacology, beta-Lactamases genetics, beta-Lactamases metabolism, Bacterial Proteins genetics, Bacterial Proteins metabolism, Anti-Bacterial Agents pharmacology
Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) are of particular concern due to the spread of antibiotic resistance genes associated with mobile genetic elements. In this study, we collected 687 carbapenem-resistant strains recovered among clinical samples from 41 hospitals in nine Southern European countries (2016-2018). We identified 11 major clonal lineages, with most isolates belonging to the high-risk clones ST258/512, ST101, ST11, and ST307. bla KPC-like was the most prevalent carbapenemase-encoding gene (46%), with bla OXA-48 present in 39% of isolates. Through the combination and comparison of this EURECA collection with the previous EuSCAPE collection (2013-2014), we investigated the spread of high-risk clones circulating in Europe exhibiting regional differences. We particularly found bla KPC-like ST258/512 in Greece, Italy, and Spain, bla OXA-48 ST101 in Serbia and Romania, bla NDM ST11 in Greece, and bla OXA-48-like ST14 in Türkiye. Genomic surveillance across Europe thus provides crucial insights for local risk mapping and informs necessary adaptions for implementation of control strategies., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

2. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.

Author

Kakaraskoska Boceska B, Vilken T, Xavier BB, Kostyanev T, Lin Q, Lammens C, Ellis S, O'Brien S, da Costa RMA, Cook A, Russell N, Bielicki J, Riddell A, Stohr W, Walker AS, Berezin EN, Roilides E, De Luca M, Romani L, Ballot D, Dramowski A, Wadula J, Lochindarat S, Boonkasidecha S, Namiiro F, Ngoc HTB, Tran MD, Cressey TR, Preedisripipat K, Berkley JA, Musyimi R, Zarras C, Nana T, Whitelaw A, da Silva CB, Jaglal P, Ssengooba W, Saha SK, Islam MS, Mussi-Pinhata MM, Carvalheiro CG, Piddock LJV, Heath PT, Malhotra-Kumar S, Sharland M, Glupczynski Y, and Goossens H

Subjects
Humans, Infant, Newborn, Amikacin pharmacology, Amikacin therapeutic use, Fosfomycin pharmacology, Fosfomycin therapeutic use, beta-Lactamases genetics, beta-Lactamases metabolism, Escherichia coli drug effects, Escherichia coli genetics, Escherichia coli isolation & purification, Developing Countries, Drug Resistance, Multiple, Bacterial genetics, Drug Therapy, Combination, Serratia marcescens drug effects, Serratia marcescens genetics, Serratia marcescens isolation & purification, Enterobacter cloacae drug effects, Enterobacter cloacae genetics, Enterobacter cloacae isolation & purification, Bacterial Proteins genetics, Bacterial Proteins metabolism, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Neonatal Sepsis microbiology, Neonatal Sepsis drug therapy, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria genetics, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections microbiology, Acinetobacter baumannii drug effects, Acinetobacter baumannii isolation & purification, Acinetobacter baumannii genetics, Microbial Sensitivity Tests, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae isolation & purification, Klebsiella pneumoniae genetics
Abstract

Gram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs. The five most prevalent bacterial isolates in the NeoOBS study (NCT03721302) are Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, Serratia marcescens and Enterobacter cloacae complex. Among these isolates, high levels of ESBL and carbapenemase encoding genes are detected along with resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens. The three new combinations show excellent in vitro activity against ESBL-producing K. pneumoniae and E. coli isolates. Our data should further inform and support the clinical evaluation of these three antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-resistant Gram-negative bacteria., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results